AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03730480 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contour Next and Contour TV3 BGMS testing by subjects with and without Diabetes
Description: Using the first blood glucose monitoring system (BGMS), which is either Contour Next or Contour TV3, subjects perform self fingerstick test and alternative site test on the palm. Staff performs fingerstick test on subject. Using the second BGMS, the palm, self test and staff tests are performed. Subjects with diabetes get a venipuncture and staff tests using both BGMS using the venous blood.
Study NCT02880345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEMBROLIZUMAB
Study NCT02880345 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: hypofractionated radiation
Study NCT01248780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: 50 mg subcutaneous (SC) injection every 4 weeks for up to 48 weeks
Study NCT01248780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo SC injections at Weeks 0, 4, 8, 12, 16, and Week 20 followed by golimumab 50 mg SC injections at Week 24 and every 4 weeks thereafter up to Week 48.
Study NCT01248780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: A stable dose of MTX (oral or injectable) will be administered to participants according to the local prescribing guidelines for up to 48 weeks.
Study NCT01953653 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Structured daily diary
Description: The intervention is a structured daily diary to describe fluctuations in key psychological and behavioral variables impacting daily risk behavior among HIV-positive young men who have sex with men (YMSM), aged 16 to 24 years old who engage in substance use and sexual risk behaviors.
Study NCT02514135 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT00742612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARC1779 Injection
Description: Study drug treatment will be initiated 1 hour prior to the induction of anesthesia with a loading dose given over 1 hour in 3 successively increasing, 20-minute step infusions. The ARC1779 treatment group will be dosed to achieve a target ARC1779 steady-state plasma concentration of 3 Ug/mL, using a loading dose infusion sequence of 0.0015 mg/kg/min for 20 minutes, 0.003 mg/kg/min for the next 20 minutes, and then 0.006 mg/kg/min for the final 20 minutes; thereafter, their maintenance infusion rate is to be 0.0006 mg/kg/min.
Study NCT00742612 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (normal saline)
Description: Study drug treatment will be initiated 1 hour prior to the induction of anesthesia with a loading dose given over 1 hour in 3 successively increasing, 20-minute step infusions. The placebo group will be dosed to a steady-state plasma concentration using a loading dose infusion sequence of 0.0015 mg/kg/min for 20 minutes, 0.003 mg/kg/min for the next 20 minutes, and then 0.006 mg/kg/min for the final 20 minutes; thereafter, their maintenance infusion rate is to be 0.0006 mg/kg/min.
Study NCT02699086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDC-1421 Capsule
Description: PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.
Study NCT05035784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fecal supernatant
Description: Fecal supernatant from a child registered in the specimen bank that matches the subject's age, gender, and weight .
Study NCT05035784 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a placebo designed to match the FMT+RCE group based on appearance including 0.9% physiological saline.
Study NCT01227577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Nilotinib was supplied as 150 mg and 200 mg hard gelatin capsules.
Study NCT01670955 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Jobelyn
Description: Jobelyn is a sorghum bicolor extract marketed as dietary supplement
Study NCT01670955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulphate + Folic Acid
Description: Ferrous Sulphate 600mg, thrice daily + Folic Acid, 5mg daily
Study NCT02896049 — intervention group
Intervention type: DEVICE
Intervention: Hyperthermia
Description: treatment with the Celsius42 Hyperthermia System additional to radiotherapy and/or chemotherapy
Study NCT04357197 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop
Description: The system will be tested to see if it can avoid hypotension
Study NCT01159587 — intervention group
Intervention type: DRUG
Intervention: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Description: Long-term secondary prophylaxis with product administered 20-30 UI /kg three times weekly
Study NCT01159587 — intervention group
Intervention type: DRUG
Intervention: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Description: On-demand treatment with product given only for bleeding episodes
Study NCT02335177 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interventional arm
Description: At home patients have both technologies for autonomy (walkers, treadmill) and tailored physical activity program performed with the help of the home carer. Intervention takes 3 months. Assessment at hospital discharge et at 3 months.
Study NCT03241225 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EM/PROTECT
Description: EM/PROTECT is a behavioral intervention for depressed elder mistreatment (EM) victims designed to work in synergy with EM mistreatment resolution services that provide safety planning, support services, and links to legal services
Study NCT03241225 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EM/MH
Description: EM/MH provides individuals experiencing elder mistreatment with support services from staff trained in linking elder mistreatment victims to community mental health services.
Study NCT01762319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Study NCT01762319 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin B6
Study NCT03356626 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ULTRACISION Harmonic Scalpel
Description: to use ULTRACISION Harmonic Scalpel when performing gastrectomy
Study NCT03356626 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ligasure Maryland
Description: to use Ligasure Maryland when performing gastrectomy
Study NCT03356626 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thunderbeat
Description: to use Thunderbeat when performing gastrectomy
Study NCT04588545 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Participants will receive radiation therapy (RT), either whole brain radiation therapy or focal brain/spine RT. The goal of RT is to palliate symptoms and improve the flow of Intrathecal (IT) therapy through the cerebrospinal fluid (CSF). As such, various RT schedules and targets are permitted. It is expected that the majority of patients will receive WBRT with 30 Gy in 10 fractions. However, shorter fractions of 20 Gy in 5 fractions of WBRT are permitted. In those patients who have more localized leptomeningeal disease in the spine, focal RT in up to 10 fractions may be administered with the exact dose left up to the discretion of the treating radiation oncologist.
Study NCT04588545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Participants will be treated at 1 of 4 dose levels of pertuzumab, beginning at 10 mg and increasing up to 80 mg or Maximum Tolerated Dose (MTD).
Study NCT04588545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Participants will be treated at a fixed dose of 80 mg trastuzumab.
Study NCT03104868 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAKE IT Strategy
Description: The TAKE IT Strategy includes:~1. Programming the electronic health record (EHR) to organize/simplify daily regimen schedules and generate electronic, tangible, print, low literacy medication education materials at every clinical encounter.~2. SMS text-messaging to remind patients when to take all their medicine.~3. A web-based patient portal that requests patients to periodically report upon their medication use, providing a continuous link between the transplant center and patient beyond routine in-person visits.~4. EHR notifications directed to the transplant center nurse coordinator if an adherence-related problem is identified by the web-based portal assessment, who then can activate appropriate staff to respond.
Study NCT05035537 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PGDT
Description: The minimally invasive continuous CI monitor (Edwards ClearSight) was used to guide an optimization of preload with the use of algorithms based on fluids, inotropes and/or vasopressors to achieve a certain goal in medium arterial pressure (MAP), cardiac index (CI) and stroke volume variation (SVV)
Study NCT01814111 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: renal sympathetic denervation
Description: The ablation catheter was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis.
Study NCT04500587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-d5
Description: Oral agent; 25 mg or 100 mg formulation
Study NCT02338674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir and telbivudine
Description: tenofovir and telbivudine administered at least 48 weeks
Study NCT03756987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine Injection
Description: Ropivacaine will be injected in the erector spinae plane
Study NCT02338674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Description: tenofovir administered at least 48 weeks
Study NCT00317980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meglumine antimoniate
Description: Meglumine antimoniate 5mg/kg/d for 20 days
Study NCT00317980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meglumine antimoniate
Description: Meglumine antimoniate 15 mg/kg/d for 20 days
Study NCT02346123 — intervention group
Intervention type: GENETIC
Intervention: Gathering of samples of genetic material
Description: The samples will be obtained from peripheral blood mononuclear cells and the genotyping of the polymorphisms will be done by real time PCR.
Study NCT03096808 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adaptive Radiotherapy
Description: ART involved modification of the radiation treatment plan during treatment course to account for temporal variations in anatomy due to changes in tumor volume and/or patients' weight loss.
Study NCT01730599 — intervention group
Intervention type: OTHER
Intervention: neurological exam
Description: motor and cognitive functions
Study NCT06294626 — intervention group
Intervention type: OTHER
Intervention: Group 1
Description: 21 cases with scaphocephaly diagnoses were included. Neuromotor development was evaluated with the Denver-II Developmental Screening Test and Alberta Infant Motor Scale.
Study NCT04246788 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive robotic rehabilitation
Description: 5 sessions per week of 30 minutes of robot-assisted rehabilitation with the G-EO system during two weeks
Study NCT04246788 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: classical physiotherapy
Description: 3 sessions per week of 30 minutes of classical physiotherapy during two weeks
Study NCT04440475 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP block
Description: Tap block description:~The skin is prepped and draped in a sterile fashion for a lateral to posterior/lateral approach to the Transverse Abdominis Plane (TAP). The Anesthesiologists use ultrasound guidance for all TAP blocks and pre mix 60cc of 0.2% ropivicaine with 10mg of preservative free dexamethasone. After the plane is identified in approximately the mid axillary line, a 17g Tuohy needle is used under ultrasound guidance to enter the potential space from an anterior approach. The needle is visualized in-plane with the ultrasound probe, traversing the exterior and interior oblique muscles and penetrating through the posterior fascia of internal oblique into the transverse abdominal plane. Once the Tuohy is in place, the needle is aspirated and the plane is hydro-dissected using 0.2% Ropivicaine with 10mg of dexamethasone. The anesthesiologist will use 30ml of 0.2% Ropivicaine on each side.
Study NCT01128933 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal artery stenting
Study NCT03532451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 480 mg intravenously (IV) over approximately 30 minutes every 4 weeks for 2 neo-adjuvant doses (week 0 and 4) followed by RC with bilateral (standard or extended) PLND as soon as possible but within 6 weeks after the last neoadjuvant infusion.
Study NCT03532451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab/Lirilumab
Description: Nivolumab 480 mg IV over approximately 60 minutes every 4 weeks for 2 neo-adjuvant doses (week 0 and 4) with at least a 30 minute rest between infusions followed by lirilumab 240 mg IV over approximately 60 minutes every 4 weeks for 2 neo-adjuvant doses (week 0 and 4) followed by RC with bilateral (standard or extended) PLND as soon as possible but within 6 weeks after the last neoadjuvant infusion.
Study NCT02375854 — intervention group
Intervention type: OTHER
Intervention: Observation
Study NCT04421677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylbutyrate Oral Tablet
Description: Phenylbutyrate, an orally active chemical chaperone approved by the US Food and Drug Administration for treatment of urea cycle disorders, mimics the function of intracellular molecular chaperones in preventing protein aggregation and oligomerization.
Study NCT05225090 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Smartphone App
Description: Medisafe is a Med_App that is free and has been used in several studies evaluating medication adherence. Patients will receive individualized instruction and be followed for 12 weeks. The researcher will show the patients how to input current medication list, set up medication reminders and track if daily doses have been taken using the App (20 minute training session). After the participant has input their medication information into the app, the researcher will assist the participant in adding an optional Medifriend who will be alerted if the participant misses a dose as an option. The participant will also be provided with written instructions about the Medisafe app to take home for reference. At each office visit (4, 8, and 12 weeks) participants will complete a medication checklist and reconciliation form with the research staff. Participants will also be asked to send a medication status report through the Medisafe app.
Study NCT03021200 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Green indocianine
Description: Laser fluorescence using green indocianine guiding the surgical procedure.
Study NCT03373240 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU plus Cognitive Remediation Program
Description: Treatment normally received at this clinic that generally includes individual or group sessions and regular urine monitoring PLUS computerized games that focus on cognitive-affective self-regulatory processes.
Study NCT03373240 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: TAU plus Control Tasks
Description: Treatment normally received at this clinic that generally includes individual or group sessions and regular urine monitoring PLUS a series of computerized word games.
Study NCT04440033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baseline assessment of demographic, anthropometric and clinical characteristics
Description: * Age~* Sex~* Height~* Body weight~* Handedness~* Medication use~* Blood pressure~* Global cognition (Montreal Cognitive Assessment)~* Fear of falling (Shortened Iconographical Falls Efficacy Scale)~* History of falls (number of falls in the past month)~* Time since diagnosis and symptom onset~* Disease severity (UPDRS part III, Hoehn and Yahr)~* Non-motor symptoms (UPDRS part I)~* Motor symptoms (UPDRS part III)~* Motor complications (UPDRS part IV)~* Disease-dominant side (UPDRS part III)~* Freezing of gait (New Freezing of Gait Questionnaire)
Study NCT04440033 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Baseline assessment of demographic, anthropometric and clinical characteristics
Description: * Age~* Sex~* Height~* Body weight~* Handedness~* Medication use~* Blood pressure~* Global cognition (Montreal Cognitive Assessment)~* Fear of falling (Shortened Iconographical Falls Efficacy Scale)~* History of falls (number of falls in the past month)
Study NCT03756987 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline will be injected in the erector spinae plane.
Study NCT02819362 — intervention group
Intervention type: DEVICE
Intervention: MRI
Description: The magnetic resonance imaging (MRI) will be performed before the two-step surgery: a ductal-MRI sequence (highly weighted sagittal T2) - followed by sequence with axial plane, T2, T1, injection in dynamic sequences, subtractions.
Study NCT01952353 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoprative TACE
Study NCT04440033 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Locomotor assessments
Description: First, 9 anthropometric measurements will be taken, 39 reflective markers will be placed, and a 6-min practice walking session will be conducted to familiarize participants with self-paced treadmill walking (SPTW). Thereafter, participants will partake in 7 experimental conditions in a (semi-)randomized order:~* 3 min standing~* 3 min standing while answering semi-standardized questions~* 3 min SPTW~* 3 min SPTW while answering semi-standardized questions (SPTW-Q)~* 3 min SPTW while verbally describing a VR environment (SPTW-VR1)~* 6 min SPTW in a VR environment containing freezing of gait provoking elements (SPTW-VR2)
Study NCT04440033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Locomotor assessments
Description: First, 9 anthropometric measurements will be taken, 39 reflective markers will be placed, and a 6-min practice walking session will be conducted to familiarize participants with self-paced treadmill walking (SPTW). Thereafter, participants will partake in 7 experimental conditions in a (semi-)randomized order:~* 3 min standing~* 3 min standing while answering semi-standardized questions~* 3 min SPTW~* 3 min SPTW while answering semi-standardized questions (SPTW-Q)~* 3 min SPTW while verbally describing a VR environment (SPTW-VR1)~* 6 min SPTW in a VR environment containing freezing of gait provoking elements (SPTW-VR2)
Study NCT04440033 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Speech assessments
Description: * Acoustic analysis (including voice reports and formant analysis), video recording and motor speech profile (including analysis of diadochokinesis, voice, standard syllabic rate, intonation and second formant (F2)).~* Spontaneous speech production will be assessed by answering semi-standardized questions based on the Aachen Aphasia Test and by describing a VR environment projected on a 180-degree cylindrical screen~* The Speech Handicap Index (a 15-item self-reported questionnaire)
Study NCT04440033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speech assessments
Description: * Acoustic analysis (including voice reports and formant analysis), video recording and motor speech profile (including analysis of diadochokinesis, voice, standard syllabic rate, intonation and second formant (F2)).~* Spontaneous speech production will be assessed by answering semi-standardized questions based on the Aachen Aphasia Test and by describing a VR environment projected on a 180-degree cylindrical screen~* The Speech Handicap Index (a 15-item self-reported questionnaire)
Study NCT04440033 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Audiology assessments
Description: * Otoscopy~* Tympanometry~* Pure tone audiometry~* Otoacoustic emissions~* Video Head Impuls Test~* Cervical Vestibular Evoked Myogenic Potentials~* Ocular Vestibular Evoked Myogenic Potentials~* Oculomotor function testing~* Positional testing~* Static visual acuity test~* Dynamic visual acuity test~* Dizziness Handicap Inventory (a 25-item self-assessment inventory)
Study NCT04440033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audiology assessments
Description: * Otoscopy~* Tympanometry~* Pure tone audiometry~* Otoacoustic emissions~* Video Head Impuls Test~* Cervical Vestibular Evoked Myogenic Potentials~* Ocular Vestibular Evoked Myogenic Potentials~* Oculomotor function testing~* Positional testing~* Static visual acuity test~* Dynamic visual acuity test~* Dizziness Handicap Inventory (a 25-item self-assessment inventory)
Study NCT03844347 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress management sessions
Description: Stress management sessions are proposed to the patients and consist of small exercises focused on breathing and bodily sensations. Each accompanying person has access to different exercises. The sessions are adapted to the state of the patient to promote his well-being, before or after his/her operation. The duration of a preoperative session is 1 hour, the duration of the postoperative sessions is 15 minutes.
Study NCT04444076 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REGENETEN Bioinductive Implant
Description: REGENETEN bioinductive Implant,a reconstituted bovine origin type I collagen mesh with a proprietary high porosity system that is commercialized sterile, dehydrated and desiccated in two sizes (20x26mm and 25x31mm). It will be implanted following supraspinatus tendon repair.
Study NCT04583618 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Conjugate Vaccine - formulation 1-SP0202-IIb
Description: Pharmaceutical form:Suspension for injection Route of administration: intramuscular